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RadiosensitisationBackground and purpose: Nelfinavir can enhance intrinsic radiosensitivity, reduce hypoxia and improve
vascularity. We conducted a phase II trial combining nelfinavir with chemoradiotherapy (CRT) for locally
advanced inoperable pancreatic cancer (LAPC).
Materials and methods: Radiotherapy (50.4 Gy/28 fractions; boost to 59.4 Gy/33 fractions) was adminis-
tered with weekly gemcitabine and cisplatin. Nelfinavir started 3–10 days before and was continued dur-
ing CRT. The primary end-point was 1-year overall survival (OS). Secondary end-points included
histological downstaging, radiological response, 1-year progression free survival (PFS), overall survival
(OS) and treatment toxicity. An imaging sub-study (n = 6) evaluated hypoxia (18F-Fluoromisonidazole-
PET) and perfusion (perfusion CT) during induction nelfinavir.
Results: The study closed after recruiting 23 patients, due to non-availability of Nelfinavir in Europe. The
1-year OS was 73.4% (90% CI: 54.5–85.5%) and median OS was 17.4 months (90% CI: 12.8–18.8). The 1-
year PFS was 21.8% (90% CI: 8.9–38.3%) and median PFS was 5.5 months (90% CI: 4.1–8.3). All patients
experienced Grade 3/4 toxicity, but many were asymptomatic laboratory abnormalities. Four of 6
patients on the imaging sub-study demonstrated reduced hypoxia and increased perfusion post-
nelfinavir.
Conclusions: CRT combined with nelfinavir showed acceptable toxicity and promising survival in pancre-
atic cancer.
 2016 The Authors. Published by Elsevier Ireland Ltd. Radiotherapy and Oncology 119 (2016) 306–311
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).Pancreatic ductal adenocarcinoma is one of the most aggressive
cancers, and surgical resection is the only potentially curative
option [1]. However, the majority of patients are diagnosed in late
stages. Locally advanced pancreatic cancer (LAPC) is associated
with a poor prognosis [2]. Definitive chemo-radiotherapy (dCRT)
is considered a treatment option LAPC, however the overall
survival (OS) with upfront dCRT ranges from 7–12 months [3,4].
Pancreatic tumours are inherently resistant to radiotherapy, and
dose escalation is limited by potential toxicity from irradiation ofsurrounding organs at risk (OARs), most commonly the gastro-
intestinal tract [5]. Hypoxia and hypovascularity contribute to
radioresistance in pancreatic cancer [6–9]. We have previously
demonstrated that the anti-retroviral drug Nelfinavir can enhance
intrinsic radiosensitivity, reduce hypoxia and improve vascularity,
potentially through Akt inhibition [10–12].
A phase I study (ARC I) combining nelfinavir with gemcitabine
and cisplatin-based CRT in LAPC, demonstrated acceptable toxicity
[13]. We therefore designed a single arm phase II trial to assess the
efficacy and tolerability of this regimen. We hypothesised that the
addition of Nelfinavir to CRT would improve OS with acceptable
toxicity. In order to objectively demonstrate changes in hypoxia
and perfusion due to Nelfinavir treatment, an imaging sub-study
was included.
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Study design and patients
ARC II was a single-centre, open label, phase 2 trial. Patients
aged 18 years or older were eligible if they had histology or cytol-
ogy proven pancreatic, ampullary or intra-pancreatic bile duct ade-
nocarcinoma where the disease was locally advanced, inoperable
and non-metastatic (or medically inoperable due to patient co-
morbidity). Patients were required to have Karnofsky performance
index P70%, adequate liver, renal and bone marrow function, and
estimated life expectancy P12 weeks. All patients were staged
with FDG PET-CT and discussed at the pancreatic multi-
disciplinary meeting (MDM) where specialist pancreatic surgeons,
radiologists and oncologists agreed on decision regarding inoper-
ability and suitability for CRT. The local research ethics committee
approved the study. All patients provided written informed con-
sent. The ARC II trial was funded and sponsored by the University
of Oxford. In June 2013 the protocol was amended to allow
patients to enter a functional imaging sub-study (described below).Study procedures
All patients received upfront CRT (Fig. 1). Patients underwent
contrast-enhanced planning computer tomography (CT) simula-
tion after a 2 h fast with 100–200 ml water as oral contrast. The
gross tumour volume (GTV) with a margin of 2 cm cranio-caudal
and 1.5 cm circumferential margin received 59.4 Gy in 33 daily
fractions. Uninvolved loco-regional nodes received 50.4 Gy in 28
fractions. Daily online cone beam CT was used for treatment veri-
fication. Gemcitabine (1000 mg/m2) and Cisplatin (30 mg/m2)
were given on weeks 1, 2, 4 and 5 during radiotherapy. Nelfinavir
(1250 mg bd daily) was started 3 days (this was increased to
10 days following imaging amendment) prior to radiation, and
continued until the last day of CRT. Following CRT all patients were
evaluated for resectability. Adjuvant Gemcitabine for 6 months
was recommended, but not mandated.
Treatment toxicity was assessed as per Common Terminology
Criteria of Adverse Events (CTCAE version 4.0). Treatment compli-
ance of Nelfinavir was assessed by tablet count. Clinic assessments
including blood tests (haematological and biochemical tests,
CA19.9) were performed at baseline, weekly during CRT, 6–
8 weeks after CRT and 3 monthly thereafter until 12 months after
trial entry. CT scan was performed at baseline, 6–8 weeks after
completion of CRT, and 3 monthly until 12 months or progression.
PET scan was performed at baseline and 6–8 weeks after comple-
tion of CRT. Following treatment, all patients were discussed at
the MDM for resectability. Treatment after progression and patient
management beyond 12 months were as per investigator choice.Functional imaging sub-study
For the imaging sub-study, patients underwent 18F-
Fluoromisonidazaole-PET/CT (FMISO-PET) and perfusion CT (pCT)
24–48 h prior to starting nelfinavir and on day 6 or 7 of nelfinavir
treatment.Fig. 1. ARC-II trAssessment of peripheral blood mononuclear cell (PMBC) Akt
phosphorylation
Phosphorylated Akt (pAkt) is downstream target of nelfinavir.
pAkt (Ser 437) expression was assessed in PBMC using western
blot as previously described [13].End-points and statistical analysis
The primary end-point of the study was 1-year OS after trial
entry. Secondary end-points included histopathological downstag-
ing (in resected patients), RECIST-based response (CT scan) and
FDG PET-based response to therapy, 1-year progression free sur-
vival (PFS), OS, site of treatment failure and treatment toxicity.
The sample size calculation was based on the proportion surviv-
ing to 1 year (it was not expected that any patients would be lost to
follow-up). If this proportion was 55% or greater treatment would
be considered promising; if 40% or less, it would not be investi-
gated further. Based on the above parameters and using a power
of 80% and a significance level of 10%, the Fleming design requires
49 patients to take part in the study. If 27 or more patients are alive
at 1 year, this will be taken as a sign of promising activity worth
further investigation.
All analysis was undertaken using Stata 13.1 (StataCorp LP, Col-
lege Station, TX, USA). Descriptive statistics are presented with
mean (SD) for continuous variables, and numbers and percentages
for binary or categorical variables. Proportions of patients still alive
at 1 year are reported with 90% confidence intervals and a signifi-
cance level of 10% was used for the sample size calculation.
This trial was registered at European Clinical Trials Register
(EudraCT Number 2008-006302-42).Results
Follow-up and survival
Between January 2010 and July 2014, 23 patients were entered
into the study. The study was discontinued in July 2014 following
unavailability of Nelfinavir in Europe. The patient flow is shown in
the CONSORT diagram (Fig. 2). Patients were followed until death,
progression or 12-month assessment. Table 1 summarizes the
baseline patient and tumour demographics. Median follow-up
time was 14 months (IQR: 8.4–18.5) and all 23 patients were
assessable for the primary end-point. Nineteen participants have
died at time of analysis. Cause of death was related to pancreatic
cancer in 17 participants; one participant died from a pulmonary
embolism and in the remaining participants the cause of death
was unknown.
The 1-year OS after trial entry was 73.4% (90% CI: 54.5–85.5%).
The median OS was 17.4 months (90% CI: 12.8–18.8). The corre-
sponding Kaplan–Meier graph is displayed in Fig. 3A. The 1-year
PFS after trial entry was 21.8% (90% CI: 8.9–38.3%). The median
PFS was 5.5 months (90% CI: 4.1–8.3). The corresponding Kaplan–
Meier graph is displayed in Fig. 3B.
Progression occurred in 19 participants (17 of whom died
during follow-up). The site of first progression was local in 4 andial design.
Assessed for eligibility (n=39)
Excluded (n=16)
Not meeting inclusion criteria (n=10)
Declined to participate (n=6)
Allocated to intervention (n=23)
Received allocated intervention (n=23)
Did not start treatment (n=0)
Analysed (Intention to treat) (n=23)
Excluded from analysis (n=0)
Enrolled (n=23)
Withdrew consent (n=0)
Fig. 2. Consort diagram summarising the flow of patients.
Table 1
Patient and tumour characteristics at baseline in the entire cohort (n = 23).
Age in years: mean (SD) 64.7 (7.27)
Sex: female: male [n (%)] 10 (43.5%): 13 (56.5%)
% Karnofsky performance status [n (%)]
>80 15 (65.2%)
70–80 7 (30.5%)
Not documented 1 (4.3%)
Enrolment to start of treatment in days (median;
IQR; range)
14; 9, 17; 4–23
Tumour diameter (mm) (mean; IQR; SD; range) 33.5; 28, 40; 9.24;
16–51
CA19-9 concentration U/ml (median, IQR) 387 (68,1711)
SD: standard deviation; IQR: inter quartile range.
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peritoneum (n = 5), liver (n = 5), lung (n = 3), both liver and lung
(n = 1) or mediastinal node (n = 1).
Median follow-up time for patients with local progression was
18.3 months (IQR: 13.3–24.9). Nineteen of 23 patients were evalu-
able for local control at 1 year (2 died during follow up before1 year Overall survival - 73.4%
        95%CI (54.5% to 85.5%)
    Median Overall survival 17.4 months
           95%CI (12.8 to 18.8)
0.
00
0.
25
0.
50
0.
75
1.
00
23 18 14 8 5 3 0
Number at risk
0 6 12 18 24 30 36
time to death from study entry (months)
ARC-II Overall Survival
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Fig. 3. Clinical outcome in patients treated within the ARC-II clinical trial. Kapla12 months; 1 did not complete treatment and 1 died at the end
of treatment from pulmonary embolism). Twelve patients (12/19,
63.1%) had no evidence of local progression at 1 year. Additionally,
neither of the two patients who died within 12 months of follow-
up had evidence of local progression at the time of last CT scan.
The objective disease response by RECIST was: complete – nil;
partial – 5 (21.7%); stable – 10 (43.5%); progression – 6 (26.1%).
Two participants were non-evaluable – one had received less than
14 days of Nelfinavir (discontinued due to persistent hyperbilirubi-
naemia) and the other died due to a pulmonary embolism prior to
end of treatment. Two patients (8.7%) underwent a resection, both
had negative (R0) resection margins. The pathological stages of the
two patients were pT0pN0M0, L0V0R0, Gx and pT3pN1M0,
L1V0R0, G2, respectively. At the time of analysis, one resected
patient was alive and progression free 13.9 months from study
entry. The other patient relapsed with lung metastasis and sur-
vived 31.5 months from study entry.Toxicity and treatment tolerance
The main Grade 3–4 toxicities are outlined in Table 2. All
patients experienced Grade 3/4 toxicity. Asymptomatic Grade 3–
4 metabolic (laboratory) adverse events were seen in 10 (43.5%)
patients. Grade 3–4 lymphopenia, a well-recognised feature of Nel-
finavir, was seen in 20 (87%) patients but did not require support-
ive treatment. Common Grade 3/4 non-haematological toxicities
were diarrhoea (n = 5, 21.7%), nausea/vomiting (n = 5, 21.7%), fati-
gue (n = 4, 17.4%) and infection (n = 3, 13%). One patient died dur-
ing the final week of treatment from pulmonary embolism.
Supplementary Table 1 shows treatment tolerance during CRT.
Radiotherapy was well tolerated, with 73.9% of patients receiving
full dose radiation and 87% of patients receiving at least 54 Gy.
Similarly at least 87% of the participants received 80% or more dose
of Nelfinavir. Concomitant chemotherapy was less well tolerated
but 78.3% of participants still received at least 80% of the protocol
dose.Functional imaging, CA19.9 response and phospho-AKT assessment
FDG-PET
Median FDG SUVmax pre- and post-CRT was 7.6 (range 2.6–15.6)
and 3.8 (1.6–7.9) respectively (p = 0.002). The median change (%D)
in FDG SUVmax was 44.2%. Patients with %D SUVmax > median had
a median OS of 23.0 months compared to 14.6 months with %D
SUVmax < median (p = 0.01).1 year progression free survival - 21.8%
        95%CI (8.9% to 38.3%)
    Median Progression free survival 5.5 months
           95%CI (4.1 to 8.3)
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n–Meier estimates of (A) Overall survival and (B) progression-free survival.
Table 2
Adverse events of CTCAE (version 4) Grade 3–4.
Toxicity Number of participants: n (%)
Any Grade 3–4 effects 23 (100%)
Haematological 13 (56.2%)
Haemoglobin 0 (0%)
Leucocytes 7 (30.4%)
Absolute neutrophil count 2 (8.7%)
Platelets 9 (39.1%)
Lymphocytes 20 (87.0%)
Non-haematological 23 (100%)
Constitutional symptoms 5 (21.7%)
Fatigue 4 (17.4%)
Weight loss 0 (0%)
Syncope 1 (4.3%)
Other 0 (0%)
Dermatological symptoms 0 (0%)
Gastrointestinal symptoms 8 (34.8%)
Diarrhoea 5 (21.7%)
Nausea or vomiting 5 (21.7%)
Anorexia 0 (0%)
Other 4 (17.4%)
Infection 3 (13.0%)
Sepsis 2 (8.7%)
Cholangitis 1 (4.3%)
Other 0 (0%)
Vascular 1 (4.3%)
Thrombosis, thrombus or embolism 1 (4.3%)
Other 0 (0%)
Metabolic (laboratory) 10 (43.5%)
Liver 7 (30.4%)
Other 5 (21.7%)
Other 2 (8.7%)
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Four of 6 patients recruited to this sub-study had reduced f-
MISO retention with corresponding increase in pCT derived blood
flow (BF) post-nelfinavir. Mean change in f-MISO-k3 (2 tissue com-
partmental model) – was 50.3% vs 6% and BF 20.1 vs 7.1% in
responders vs non-responders.
CA19.9
The median CA19.9 level at baseline was 387 U/ml (IQR: 68–
1711). At week 13, this dropped to 122 U/ml (IQR: 27–410). The
median change in CA19.9 from baseline to week 13 was 429 U/
ml (IQR: 1992 to 19). A decline in CA19.9 was not predictive
of overall or progression free survival.
Phospho-AKT assessment
Serial blood measurement of phospho-AKT in PBMCs was avail-
able in 13 patients. Eight of 13 patients demonstrated a reduction
in pAKT 7 days after initiation of treatment, consistent with Nelfi-
navir effect.Post-CRT chemotherapy and 2nd line treatment
Following CRT, six patients received adjuvant Gemcitabine, two
of whom progressed during treatment. Ten patients received
second-line treatment on progression, of whom 4 received gemc-
itabine and 6 patients received non-gemcitabine regimen [oxalipla
tin–capecitabine (n = 3), FOLFIRINOX (n = 2), mitomycin (n = 1)].
Discussion
The present phase II study reports the clinical outcome in 23
patients with LAPC treated with CRT plus nelfinavir. The median
and 1-year OS were 17.4 months and 73.4%, respectively. Failure
at first relapse was local in 4 patients only with a 1-year local con-
trol rate of 63.1%. Although incidence of Grade 3/4 toxicity washigh, 87% of patients received 90% radiation dose; 78.3% and 87%
of patients received at least 80% dose of chemotherapy and nelfi-
navir respectively, suggesting that the toxicity was manageable.
The prognosis for patients with LAPC is poor [1] and the role of
RT in this disease remains controversial, particularly due to the
high incidence of early metastatic spread [3,4,14]. However, 30%
of LAPC never develop metastases [15] and local tumour progres-
sion represents a significant cause of disease-related morbidity
and mortality [16,17]. In ARCII, the predominance of systemic fail-
ures despite patient selection though PET-CT suggests that in addi-
tion to imaging, appropriate molecular markers of early metastasis
like SMAD4, p53 [15,18] needs to be investigated to select patients
who are most likely to benefit from radiation.
Previous studies assessing efficacy of upfront CRT has reported
OS outcomes of approximately 7–12 months [19–23] and inade-
quate adjuvant chemotherapy has been implicated in the poor sur-
vival seen in a previous dCRT trial [30]. More recently there has
been a shift in practice to using 3–4 months of induction
chemotherapy to select patients for CRT, as this has demonstrated
OS rates of approximately 11–19 months [24–29]. The median OS
of 17.4 months observed in ARCII is superior to historical survival
rates seen after upfront dCT and suggests that in appropriately
selected patients this could still be an option, and may be a useful
approach particularly where local symptoms dominate or where
downstaging to surgical resectability is still considered a
possibility.
To date, only phase I trials of nelfinavir in combination with
(chemo)radiation have been conducted in different tumour types
including pancreas [13,31–34]. In these studies Grade 3–4 toxicity
varied between 17% and 46%. The toxicity profile in ARC II was con-
sistent with that seen in the phase I pancreatic study [13] but
higher than reported in recent pancreatic phase II–III CRT trials
[24,26]. However, the toxicity pattern suggests that this is more
likely to have resulted from the concomitant Gem-Cis chemother-
apy, higher RT dose and the large RT field rather than from nelfi-
navir itself [35].
Although initially designed as an inhibitor of the human
immunodeficiency virus (HIV) protease, nelfinavir also inhibits
Akt phosphorylation and activation [10,36] that can radiosensitise
tumours [10,12,37]. Notably, we have recently found that nelfi-
navir enhances the response of pancreatic cancer cells to radiother-
apy in normoxic and hypoxic conditions, both in the absence and
presence of pancreatic stellate cells (PSCs). In-vivo, administration
of nelfinavir resulted in more profound radiosensitisation in PSN-1
xenografts when co-injected with PSCs (Al Assar et al., under
review). Nelfinavir can decrease hypoxia and improve blood flow
in xenograft and spontaneous mouse tumour models [10,11]. In
ARC II, similar changes in hypoxia and perfusion were demon-
strated by FMISO-PET and pCT, although these were exploratory
end-points. This is the first clinical study to demonstrate improved
tumour oxygenation and perfusion using a biological agent in pan-
creatic cancer and suggests potential role of imaging biomarkers
for patient selection in future trials.
The above preclinical and clinical findings on nelfinavir are
important in the context of pancreatic cancer microenvironment.
The hypovascularised immunosuppressive desmoplastic stroma
mediates chemo- and radioresistance and promotes progression
[8,9,38–40]. Hence, nelfinavir might constitute a promising agent
to modify the tumour microenvironment towards a more physio-
logical state to improve the clinical outcome after CRT as it is sug-
gested by preclinical data (Al-Assar et al. submitted to Radiother
Oncol).
Our study had several shortcomings. Although the results are
promising, the benefits of nelfinavir over and above CRT cannot
be ascertained, as this is not a randomised study. Secondly, the
outcome from this trial needs to be interpreted with caution as it
310 ARCII: nelfinavir plus chemoradiotherapy for locally advanced pancreatic cancerclosed early. Thirdly, the predominance of systemic failure sug-
gests that induction chemotherapy may have allowed better selec-
tion of patients for CRT, however the study was designed prior to
reporting of SCALOP and LAP07 [24,26]. Finally, the large radiation
fields used in this study to encompass uninvolved regional lymph
nodes may not be necessary [41,42] and may have contributed to
the high incidence of Grade 3–4 toxicity seen in this study. In
future trials (including SCALOP2), the radiation volume should
exclude prophylactic regional nodal irradiation.
In summary, notwithstanding these limitations, ARC II does
demonstrate that CRT can be delivered safely with Nelfinavir,
and the clinical outcome is promising. A 5-arm randomised phase
II study, SCALOP2, will open shortly in the UK and other centres in
Europe, where all patients will receive 3 months of Gemcitabine
plus Nab-Paclitaxel chemotherapy followed by randomisation to
continuing further chemotherapy, 50.4 Gy in 28 fractions
Capecitabine-based CRT (with/without Nelfinavir) and 60 Gy in
30 fractions Capecitabine-based CRT (with/without Nelfinavir).
SCALOP-2 trial will attempt to provide a more vigorous validation
of these results.
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